Fulcrum Therapeutics Inc. (FULC) Tops Q1 EPS by 1c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
May 14, 2024 8:47 AM EDTBofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $5.00 price target on Fulcrum Therapeutics (NASDAQ: FULC).
The analyst comments "FULC announced the company has entered an exclusive license agreement with Sanofi (ticker: SNY; covered by Graham Perry) for the ex-US development of losmapimod in... More
Fulcrum Therapeutics (FULC) PT Raised to $22 at Stifel
May 13, 2024 12:31 PM EDTStifel analyst Dae Gon Ha raised the price target on Fulcrum Therapeutics (NASDAQ: FULC) to $22.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "Ph.3 REACH (facioscapulohumeral muscular dystrophy [FSHD]) data in 4Q24 are the main focus for FY2024, and we're... More
